Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LL-37 for hard-to-heal venous leg ulcers
2018-000536-10Phase 2Completed
- Sponsor
- Promore Pharma
- Start
- Jun 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ll-37 in stasis ulcer and leg ulcer (3 arms), sponsored by Promore Pharma. Primary endpoint: Confirmed complete wound closure of the target ulcer. Started Jun 2018; status: completed.
02
Drugs
ll-37
03
Conditions
stasis ulcerleg ulcer
Beyond the preview
Go deeper on 2018-000536-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000536-10.